Analysis of background factors influencing long-term prognosis of patients with chronic hepatitis C treated with interferon

Intervirology

Volumn 45, Issue 1, 2002, Pages 11-19

  Yoneyama, Keiichiro ^a   Yamaguchi, Mayumi ^a   Kiuchi, Yuji ^a   Morizane, Toshio ^b   Shibata, Minoru ^c   Mitamura, Keiji ^c  

^a SHOWA UNIVERSITY   (Japan)

^b KANAGAWA DENTAL COLLEGE   (Japan)

^c SHOWA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Background factors; Chronic hepatitis C; Cirrhosis and hepatocellular carcinoma; Interferon therapy; Platelet count

Indexed keywords

INTERFERON;

ADULT; ARTICLE; CARCINOGENESIS; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DISEASE COURSE; DRUG EFFICACY; ECHOGRAPHY; FEMALE; FOLLOW UP; HEPATITIS C; HIGH RISK POPULATION; HUMAN; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; PROGNOSIS; THROMBOCYTE COUNT; TREATMENT OUTCOME;

ADULT; AGED; ANTIVIRAL AGENTS; CARCINOMA, HEPATOCELLULAR; COHORT STUDIES; FEMALE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INTERFERON-ALPHA; INTERFERON-BETA; LIVER CIRRHOSIS; LIVER NEOPLASMS; MALE; MIDDLE AGED; PLATELET COUNT; PROGNOSIS; RETROSPECTIVE STUDIES; RISK FACTORS; RNA, VIRAL; TREATMENT OUTCOME;

HEPATITIS C VIRUS;

EID: 0036219234     PISSN: 03005526     EISSN: None     Source Type: Journal    
DOI: 10.1159/000050082     Document Type: Article

References (29)

1. Spontaneous negativation of serum hepatitis C virus RNA is a rare event in type C chronic liver diseases: Analysis of HCV RNA in 320 patients who were followed for more than 3 years
2. Prospective assessment of donor blood screening for antibody to hepatitis C virus and high-titer antibody to HBcAg as a means of preventing posttransfusion hepatitis
3. Long-term clinical and histopathological follow-up of chronic posttransfusion hepatitis
4. Hepatitis C virus infection is an additive risk factor for development of hepatocellular carcinoma in patients with cirrhosis
5. A multivariate analysis of risk factors for hepatocellular carcinogenesis: A prospective observation of 795 patients with viral and alcoholic cirrhosis
6. Pathogenic factors in cirrhosis with and without hepatocellular carcinoma: A multicenter Italian study
7. Natural history of hepatitis C
8. Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis
9. The importance of cofactors in the histologic progression of minimal and mild chronic hepatitis C
10. Factors associated with cirrhosis development in chronic hepatitis C patients from an area of low prevalence
11. The long-term pathological evolution of chronic hepatitis C
12. Disease progression and hepatocellular carcinogenesis in patients with chronic viral hepatitis: A prospective observation of 2215 patients
13. Risk factors for hepatocellular carcinoma and its incidence after interferon treatment in patients with chronic hepatitis C
14. The incidence of hepatocellular carcinoma in patients with chronic hepatitis C after interferon treatment
15. Effect of interferon therapy on hepatocellular carcinogenesis in patients with chronic hepatitis type C: A long-term observation study of 1,643 patients using statistical bias correction with proportional hazard analysis
16. Interferon therapy reduces the risk for hepatocellular carcinoma: National surveillance program of cirrhotic and noncirrhotic patients with chronic hepatitis C in Japan. IHIT Study Group. Inhibition of Hepatocarcinogenesis by Interferon Therapy
17. Prospective comparison of four lymphoblastoid interferon alpha schedules for chronic hepatitis C. A multivariate analysis of factors predictive of sustained response to treatment
18. Chronic hepatitis C: The viral load per liver cell before treatment as a new marker to predict long-term response to IFN-alpha therapy
19. Comparative efficacy of a high or low dose of interferon alpha 2b in chronic hepatitis C: A randomized controlled trial
20. Analysis of genotypes and amino acid residues 2,209 to 2,248 of the NS5A region of hepatitis C virus in relation to the response to interferon-beta therapy
21. Comparison of two interferon-alpha treatment regimens characterized by an early virological response in patients with chronic hepatitis C
22. Importance of pretreatment viral load and monitoring of serum hepatitis C virus RNA in predicting responses to interferon-alpha2a treatment of chronic hepatitis C
23. Prediction of response during interferon-alpha 2b therapy in chronic hepatitis C patients using viral and biochemical characteristics: A comparison
24. Liver biopsy is a useful predictor of response to interferon therapy in chronic hepatitis C
25. Ability of prolonged interferon treatment to suppress relapse after cessation of therapy in patients with chronic hepatitis C: A multicenter randomized controlled trial
26. Remission of liver fibrosis by interferon-alpha 2b
27. Effectiveness of interferon therapy for reducing the incidence of hepatocellular carcinoma among patients with type C chronic hepatitis
28. The effectiveness of interferon therapy on occurrence of hepatocellular carcinoma in chronic hepatitis C
29. Effect of interferon-alpha on progression of cirrhosis to hepatocellular carcinoma: A retrospective cohort study